Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Atripla to MK-1439A for CNS toxicity in virologically suppressed adults with HIV-1
2015-003617-18Phase 2Unknown
- Sponsor
- Merck & Co.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Delstrigo and tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoint: Proportion of subjects with at least one CNS toxicity of at least Grade 2 intensity at Week 12. Status: unknown.
02
Drugs
Delstrigotenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2015-003617-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003617-18.